205 related articles for article (PubMed ID: 17515296)
1. Fetal nuchal translucency thickness.
Witters I; Fryns JR
Genet Couns; 2007; 18(1):1-7. PubMed ID: 17515296
[TBL] [Abstract][Full Text] [Related]
2. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience.
Spencer K; Nicolaides KH
BJOG; 2003 Mar; 110(3):276-80. PubMed ID: 12628267
[TBL] [Abstract][Full Text] [Related]
3. Screening for trisomy 21 by maternal age, fetal nuchal translucency thickness, free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A.
Kagan KO; Wright D; Baker A; Sahota D; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 Jun; 31(6):618-24. PubMed ID: 18461550
[TBL] [Abstract][Full Text] [Related]
4. Nuchal fold thickness, nasal bone absence or hypoplasia, ductus venosus reversed flow and tricuspid valve regurgitation in screening for trisomies 21, 18 and 13 in the early second trimester.
Geipel A; Willruth A; Vieten J; Gembruch U; Berg C
Ultrasound Obstet Gynecol; 2010 May; 35(5):535-9. PubMed ID: 20183867
[TBL] [Abstract][Full Text] [Related]
5. Screening for trisomy 21 by fetal tricuspid regurgitation, nuchal translucency and maternal serum free beta-hCG and PAPP-A at 11 + 0 to 13 + 6 weeks.
Falcon O; Auer M; Gerovassili A; Spencer K; Nicolaides KH
Ultrasound Obstet Gynecol; 2006 Feb; 27(2):151-5. PubMed ID: 16388509
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the ductus venosus, tricuspid blood flow and the nasal bone in second-trimester screening for trisomy 21.
Stressig R; Kozlowski P; Froehlich S; Siegmann HJ; Hammer R; Blumenstock G; Kagan KO
Ultrasound Obstet Gynecol; 2011 Apr; 37(4):444-9. PubMed ID: 20645398
[TBL] [Abstract][Full Text] [Related]
7. Relation between increased fetal nuchal translucency thickness and chromosomal defects.
Kagan KO; Avgidou K; Molina FS; Gajewska K; Nicolaides KH
Obstet Gynecol; 2006 Jan; 107(1):6-10. PubMed ID: 16394033
[TBL] [Abstract][Full Text] [Related]
8. Multicenter study of first-trimester screening for trisomy 21 in 75 821 pregnancies: results and estimation of the potential impact of individual risk-orientated two-stage first-trimester screening.
Nicolaides KH; Spencer K; Avgidou K; Faiola S; Falcon O
Ultrasound Obstet Gynecol; 2005 Mar; 25(3):221-6. PubMed ID: 15736186
[TBL] [Abstract][Full Text] [Related]
9. Maternal serum biochemistry at 11-13(+6) weeks in relation to the presence or absence of the fetal nasal bone on ultrasonography in chromosomally abnormal fetuses: an updated analysis of integrated ultrasound and biochemical screening.
Cicero S; Spencer K; Avgidou K; Faiola S; Nicolaides KH
Prenat Diagn; 2005 Nov; 25(11):977-83. PubMed ID: 16245371
[TBL] [Abstract][Full Text] [Related]
10. First trimester ultrasound screening for Down syndrome based on maternal age, fetal nuchal translucency and different combinations of the additional markers nasal bone, tricuspid and ductus venosus flow.
Abele H; Wagner P; Sonek J; Hoopmann M; Brucker S; Artunc-Ulkumen B; Kagan KO
Prenat Diagn; 2015 Dec; 35(12):1182-6. PubMed ID: 26223508
[TBL] [Abstract][Full Text] [Related]
11. If nuchal translucency screening is combined with first-trimester serum screening the need for fetal karyotyping decreases.
Marsk A; Grunewald C; Saltvedt S; Valentin L; Almström H
Acta Obstet Gynecol Scand; 2006; 85(5):534-8. PubMed ID: 16752230
[TBL] [Abstract][Full Text] [Related]
12. SURUSS in perspective.
Wald NJ; Rodeck C; Hackshaw AK; Rudnicka A
Semin Perinatol; 2005 Aug; 29(4):225-35. PubMed ID: 16104673
[TBL] [Abstract][Full Text] [Related]
13. The role of fetal nuchal translucency and ductus venosus Doppler at 11-14 weeks of gestation in the detection of major congenital heart defects.
Favre R; Cherif Y; Kohler M; Kohler A; Hunsinger MC; Bouffet N; Tanghe M; Cancellier M; Nisand I
Ultrasound Obstet Gynecol; 2003 Mar; 21(3):239-43. PubMed ID: 12666217
[TBL] [Abstract][Full Text] [Related]
14. Fetal nuchal translucency screening in 12495 pregnancies in Sardinia.
Zoppi MA; Ibba RM; Floris M; Monni G
Ultrasound Obstet Gynecol; 2001 Dec; 18(6):649-51. PubMed ID: 11844208
[TBL] [Abstract][Full Text] [Related]
15. Absence of nasal bone in fetuses with trisomy 21 at 11-14 weeks of gestation: an observational study.
Cicero S; Curcio P; Papageorghiou A; Sonek J; Nicolaides K
Lancet; 2001 Nov; 358(9294):1665-7. PubMed ID: 11728540
[TBL] [Abstract][Full Text] [Related]
16. First-trimester ultrasonographic screening for trisomy 21 using fetal nuchal translucency and nasal bone.
Sepulveda W; Wong AE; Dezerega V
Obstet Gynecol; 2007 May; 109(5):1040-5. PubMed ID: 17470580
[TBL] [Abstract][Full Text] [Related]
17. Screening for trisomy 21 in monochorionic twins by measurement of fetal nuchal translucency thickness.
Vandecruys H; Faiola S; Auer M; Sebire N; Nicolaides KH
Ultrasound Obstet Gynecol; 2005 Jun; 25(6):551-3. PubMed ID: 15880648
[TBL] [Abstract][Full Text] [Related]
18. Measurement of nuchal translucency as a single strategy in trisomy 21 screening: should we use any other marker?
Comas C; Torrents M; Muñoz A; Antolín E; Figueras F; Echevarría M
Obstet Gynecol; 2002 Oct; 100(4):648-54. PubMed ID: 12383528
[TBL] [Abstract][Full Text] [Related]
19. [Birth defects associated with increased nuchal translucency].
Mendoza-Caamal EC; Grether-González P; Hernández-Gómez M; Guzmán-Huerta M; Aguinaga-Ríos M
Ginecol Obstet Mex; 2010 Oct; 78(10):533-9. PubMed ID: 21966770
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of increased nuchal translucency as a screening test for the detection of fetal chromosomal abnormalities.
Alexioy E; Alexioy E; Trakakis E; Kassanos D; Farmakidis G; Kondylios A; Laggas D; Salamalekis E; Florentin L; Kanavakis E; Basios G; Trompoukis P; Georgiadoy L; Panagiotopoulos T
J Matern Fetal Neonatal Med; 2009 Oct; 22(10):857-62. PubMed ID: 19521928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
